A Prospective Pilot Study to Evaluate a New Marker of Ischemia in Chest Pain Triage
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02608255|
Recruitment Status : Completed
First Posted : November 18, 2015
Last Update Posted : January 4, 2017
A Single-center prospective pilot study enrolling chest pain patients. CD 26 measurement will be performed and compared to troponin µs for early triage of these patients. This novel biomarker of myocardial ischemia (CD26) will be measured at the time of first medical contact (T0) and after 30 min simultaneously o troponin Ic.
All patients aged over 18 years with chest pain which may be related to acute coronary syndrome requiring pre hospital medical contact through the Emergency Medical Service.
|Condition or disease||Intervention/treatment||Phase|
|Acute Coronary Syndrome||Other: blood samples||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||100 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Prospective Pilot Study to Evaluate a New Marker of Ischemia in Chest Pain Triage|
|Study Start Date :||January 2016|
|Actual Primary Completion Date :||November 2016|
|Actual Study Completion Date :||January 2017|
|Experimental: acute coronary syndromes||
Other: blood samples
- blood sample : dosage of CD26 [ Time Frame: 12 MONTHS ]demonstrating the early positivity of CD26 compared to ultra-sensitive troponin.
- blood sample: dosage of the copeptin [ Time Frame: 12 months ]
- blood sample: dosage of troponin [ Time Frame: 12 months ]
- blood sample : dosage of IMA [ Time Frame: 12 months ]IMA (Albumin modified by the ischaemia)
- blood sample: dosage of adenosin [ Time Frame: 12months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02608255
|Assistance Publique Hopitaux de Marseille|
|Marseille, France, 13354|
|Principal Investigator:||BONELLO laurent||AP HM|